Alkermes Shares Long-Term LYBALVI Treatment Data for Schizophrenia at SIRS 2024 Congress
Portfolio Pulse from Benzinga Newsdesk
Alkermes plc (NASDAQ:ALKS) presented long-term clinical data on LYBALVI for schizophrenia treatment at the SIRS 2024 Congress. The data comes from a phase 3 study showing LYBALVI's safety, tolerability, and effectiveness over four years. LYBALVI is approved in the U.S. for treating adults with schizophrenia and bipolar I disorder.
April 08, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alkermes presented positive long-term data on LYBALVI for schizophrenia at the SIRS 2024 Congress, indicating safety and effectiveness over four years.
The presentation of positive long-term data for LYBALVI at a prestigious congress like SIRS 2024 is likely to be viewed positively by investors and could lead to increased confidence in Alkermes' product pipeline and future revenue potential. Given LYBALVI's approval for treating schizophrenia and bipolar I disorder in the U.S., this data reinforces its market position and potential for sustained sales.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100